deferiprone has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carboni, E | 1 |
| Tatenhorst, L | 1 |
| Tönges, L | 1 |
| Barski, E | 1 |
| Dambeck, V | 1 |
| Bähr, M | 1 |
| Lingor, P | 1 |
| Dexter, DT | 1 |
| Statton, SA | 1 |
| Whitmore, C | 1 |
| Freinbichler, W | 1 |
| Weinberger, P | 1 |
| Tipton, KF | 1 |
| Della Corte, L | 1 |
| Ward, RJ | 1 |
| Crichton, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease[NCT01539837] | Phase 2 | 22 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease, modify regional brain mineralization (iron concentration) as assessed with T2* MRI in PD patients in the dentate nucleus. In previous animal studies, Deferiprone treatment reduced dentate nucleus iron content, as assessed by MRI. An increase in the T2*MRI value represents an increase in mineralization. (NCT01539837)
Timeframe: 6 months
| Intervention | ms (Mean) |
|---|---|
| Placebo | 30.74 |
| Deferiprone 20mg | 30.59 |
| Deferiprone 30mg | 29.86 |
To assess whether there were any serious adverse events in 6-month treatment with Deferiprone. (NCT01539837)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Deferiprone 20mg | 0 |
| Deferiprone 30mg | 0 |
2 other studies available for deferiprone and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation.
Topics: alpha-Synuclein; Animals; Cell Count; Deferiprone; Drug Evaluation, Preclinical; Female; Gait Disord | 2017 |
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.
Topics: Animals; Benzoates; Brain; Deferasirox; Deferiprone; Deferoxamine; Free Radicals; Immunohistochemist | 2011 |